EXPERIENCE OF IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS MANAGEMENT IN URAL FEDERAL DISTRICT: FEATURES OFOUTPATIENT-HOSPITAL INTERACTIONS

Author:

Shalaev S. V.1,Arkhipov M. V.2,Iofin A. L.3,Bykov A. N.3,Evrgafova L. V.3,Yakovleva O. E.4,Nizamova D. F.5,Balina V. A.6,Milovanova E. V.7

Affiliation:

1. Heart and Vessels Center of Tumen Regional Clinical Hospital №1; Tumen State Medical University

2. Ural State Medical University

3. Sverdlovsk Regional Clinical Hospital №1

4. Chelyabinsk Regional Cardiology Hospital

5. Heart and Vessels Center of Tumen Regional Clinical Hospital №1

6. Tumen Regional Clinical Hospital №1

7. Regional Cardiology Clinic “The Center of Cardiovascular Surgery and diagnosis”

Abstract

Idiopathic pulmonary arterial hypertension (IPAH) is a severe chronic and rapidly progressive disease with increasing pulmonary vascular resistance (PVR) due to the ongoing pathogenic processes in the vascular wall that lead to obstruction of small pulmonary arteries and arterioles. IPAH takes a small part in the structure among all forms of pulmonary hypertension (PH), the median survival of patients with IPAH before any PAH-specific therapy became available were about 2,8 years, and the average time from the manifestation of the disease to its diagnosis took 2-3 years. This article is an attempt to present an unified data of adult patients with IPAH in Ural Federal district, and describe PH patients medical care service. The article presents the experience of PH Medical Centers across Ural Federal District.

Publisher

Intermedservice Ltd

Subject

General Medicine

Reference37 articles.

1. Data of the site «Ural Federal District». Available by reference: http://uralfo.gov.ru/ (available on 29.01.2019).

2. Chazova IY, Avdeev SN, Volkov AV, Martynyuk TV, Nakonechnikov SN et al. Clinical Guidlines on the diagnosis and treatment of Pulmonary Hypertension. Therapeutic Archive 2014; 9: 4-23.

3. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat. Biotechnol. 2013; 31: 1064.

4. Martynyuk TV et al. Pulmonary Hypertension: diagnosis and treatment. Moscow, 2018, 148.

5. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011; 123: 2263–73.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3